US IPO Pipeline SEC S-1 Filings — September 25, 2026

Revenue concentration risk extreme—100% of thyroid test revenue dependent on single customer LabCorp, with no diversification plan disclosed

Pancreatic cancer test (PancraGEN) discontinued May 2025 after losing Medicare reimbursement in April 2025, eliminating a key growth driver

Stock delisted from Nasdaq and OTCQX (Aug 2025), now trading on OTCID—a severe liquidity and credibility downgrade

Replacement pancreatic cyst test requires 12-24 months development AND positive CMS reimbursement determination before launch—no timeline for revenue

Barrett's Esophagus test unlikely before 2030, offering no near-term catalyst

Standard SPAC structure with no warrants, potentially more attractive to institutional investors seeking cleaner capital structure [NEUTRAL/BULLISH]

Forward purchase agreement with Fund III guarantees minimum $20M additional capital at business combination, reducing deal failure risk

24-month completion window provides ample time for target identification vs typical 18-month SPACs

Multiple capital raises (private placements 2021, 2024; ATM 2021-2023; Roth Capital agreement 2023-2025) indicate persistent cash burn and inability to achieve profitability

Continued operating losses for fiscal years 2023-2025 with no disclosed path to profitability—high risk of shareholder dilution

100% reliance on LabCorp for thyroid test revenue—loss of this relationship would be catastrophic

CMS reimbursement denial for PancraGEN already occurred; similar risk for any future test (pancreatic cyst, Barrett's Esophagus)

New pancreatic cyst test has 12-24 month development timeline plus CMS approval requirement—no revenue visibility until at least late 2028

Trading on OTCID severely limits institutional investment and creates potential for manipulation

No business combination target identified and no substantive discussions initiated—pure blind pool risk

Public shareholders can redeem shares, and redemptions above 15% require prior consent—potential for failed deal if large redemptions occur

Continued operating losses with reliance on multiple capital raises suggests potential going concern issues if financing markets tighten

Multiple ATM agreements (2021-2023) and private placements indicate aggressive capital raising that dilutes existing shareholders

Global molecular diagnostics market growing at 11.1% CAGR to $75.9B by 2034, but Interpace is losing share due to product discontinuation and delisting

If CMS reimbursement is obtained for new pancreatic cyst test (2028+), stock could re-rate significantly from distressed levels—high risk/high reward

Low-float, heavily shorted micro-cap on OTCID could see significant volatility on any positive news

$10/share IPO with 24-month window and $20M backstop from Fund III offers downside protection for risk-tolerant investors

Experienced sponsor (TCGX) with no sector restrictions can pursue any attractive target—potential for high-growth acquisition

If Chemomab's R&D pipeline yields positive data, the business combination could unlock value for early investors

Snowdrift Parent may be acquiring Chemomab at a distressed valuation—potential for significant upside if pipeline succeeds

All three filings target healthcare/biotech—suggests sector is attractive for capital formation; investors can gain diversified exposure through IPO allocations

Chemomab's multiple financing rounds (private placements, ATMs, Roth Capital agreement) and Interpace's S-1 highlight that biotech/diagnostics companies require constant external capital—investors should expect dilution as a feature, not a bug [IMPLICATION: Favor companies with clear path to profitability]

TCGX's no-warrant structure and 24-month window suggest SPAC terms are becoming more investor-friendly post-2021 boom/bust [IMPLICATION: SPACs may offer better risk/reward for patient investors]

Interpace's delisting and product discontinuation contrast with 11.1% market CAGR—suggests winners and losers will diverge sharply based on reimbursement and commercial execution [IMPLICATION: Focus on companies with diversified revenue and CMS coverage]

Interpace's S-1 demonstrates that micro-cap IPOs carry extreme risks—single customer dependency, regulatory overhang, and OTC trading—requiring deep due diligence [IMPLICATION: Avoid micro-cap IPOs without clear competitive moats]

None of the three filings disclose insider purchases, suggesting management teams are not signaling conviction with their own capital [IMPLICATION: Skepticism warranted for all three offerings]

Monitor for pricing and demand—if IPO fails or prices below range, signals extreme investor skepticism [Date: TBD, likely Q4 2026]

Any update on pancreatic cyst test reimbursement could be a major catalyst [Date: TBD, likely 2028+]

First target identification will be key catalyst; watch for sector focus and valuation [Date: Within 24 months of IPO]

High redemptions (>15%) could threaten deal completion; monitor proxy filings [Date: At business combination vote]

S-4 is preliminary; watch for definitive agreement and shareholder vote [Date: Likely Q1-Q2 2027]

Any clinical trial results could significantly impact deal valuation [Date: TBD, monitor company press releases]

Monitor for additional S-1 filings in diagnostics/therapeutics to gauge sector appetite [Date: Ongoing]

Any changes to SPAC regulations could impact TCGX's offering structure [Date: Ongoing]